Latest and Past News
-
FDA denies approval of Biomarin’s FVIII gene therapy
In a decision that surprised many, the U.S. Food and Drug Administration (FDA) last week denied approval of Biomarin’s FVIII gene therapy, branded Roctavian. The...
-
Management of comorbidities in bleeding disorders
Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again...
-
Substitution therapy
Hemlibra (emicizumab) is indicated in Canada for hemophilia A patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the...
-
Plasma Saves Lives: Addressing the COVID-19 Pandemic
The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the...
-
In my time – Paulette
While preparing for the CHS’ national ageing retreat in 2018, Learning to learn and passing it on, we recognized that we had an opportunity...
-
In my time – Peter
While preparing for the CHS’ national ageing retreat in 2018, Learning to learn and passing it on, we recognized that we had an opportunity...
-
In my time – Colin
While preparing for the CHS’ national ageing retreat in 2018, Learning to learn and passing it on, we recognized that we had an opportunity...
-
In my time – John and Donna
While preparing for the CHS’ national ageing retreat in 2018, Learning to learn and passing it on, we recognized that we had an opportunity...
-
Hemophilia Research Million Dollar Club – Report from the chair
The Hemophilia Research Grants Review Committee, under the chairmanship of Dr. Manuel Carcao, met earlier this year and announced the 2020 grant recipients for the...
-
Update of Phase 2b trial of UniQure’s AMT-061 gene therapy trial in hemophilia B
Dr. Steven Pipe, Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program in Ann Arbor Michigan, presented an update at the World Federation of...
-
New hemophilia guidelines introduced at WFH Virtual Summit 2020
The global bleeding disorder community received an advance look at new international guidelines for the management of hemophilia at the WFH Virtual Summit 2020, at...
-
Inhibitors – think differently
The development of inhibitory antibodies to therapeutic FVIII in up to 40% of severe hemophilia A (HA) patients is a major complication in the treatment...
-
Musculoskeletal hot topic debates
In this session, three “hot topics” related to muscle, bone and joint health in people with bleeding disorders were debated by experts in their fields:...
-
OCTOSTIM SPRAY discontinued
Toronto, July 22, 2020 – Ferring Pharmaceuticals has discontinued production of OCTOSTIM SPRAY (150 mpg DIN 02237860) for the treatment of mild and moderate hemophilia A...